HBI-8000, a Class I Histone Deacetylase (HDAC) Inhibitor, in Combination with Nivolumab for Treatment of Anti-PD(L)1-Naive Advanced Melanoma: Final Analysis of Study HBI-8000-302
Nikhil I. Khushalani, Andrew Brohl, Joseph Markowitz, Heather Yeckes-Rodin, Lori McCormick, Charlie Liu, Mireille Gillings, Gloria Lee, and Zeynep Eroglu, H. Lee Moffitt Cancer Center, Tampa FL, Hematology-Oncology Associates of the Treasure Coast, Port. St. Lucie, FL, HUYABIO International, San Diego, CA, USA
AHA 2024 HBI-3000 Protective MOA in AF Patients
Jay W. Mason MD, Denis Roy MD, Gary T. Elliott PhD, Suzanne J. Romano PhD, Charles Pollack MD, Mireille Gillings PhD, Jerome B. Riebman MD
HDAC Inhibitors: Novel Therapies in Combination with Immune Checkpoint Inhibitors for Treatment of Advanced and Unresectable Melanoma – A Mini Review
John Ning, Farbod Shojaei, Mireille Gillings, Fairooz Kabbinavar & Lalitha Aiyer. Biomedical Journal of Scientific & Technical Research (April 19, 2022)
HBI-8000, HUYABIO Lead Clinical Program, is a Selective Histone Deacetylase Inhibitor with Therapeutic Benefits in Leukemia and in Solid Tumors
Farbod Shojaei, Bob Goodenow, Gloria Lee, Fairooz Kabbinavar & Mireille Gillings. Frontiers in Oncology, Cancer Molecular Targets and Therapeutics (2022)
The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors
Bissonnette et al. BMC Cancer (2021) 21:969
Society for Immunotherapy of Cancer (SITC)
November 9-14, 2020
Significant anti-tumor activity of HBI-8000, a class I histone deacetylase inhibitor (HDACi) in combination with nivolumab (NIVO) in anti-PD1 therapy-naïve advanced melanoma (TN-Mel)
American Heart Association (AHA) Scientific Sessions
November 16-18, 2019
HBI-3000: A Novel Drug for Conversion of Atrial Fibrillation
– Phase 1 Study Results
Society for Immunotherapy of Cancer (SITC)
November 7-11, 2018
A Phase 1b/2 Study of the Safety and Efficacy of HBI-8000-Nivolumab Combination in
Melanoma (MEL), Renal Cell Carcinoma (RCC) and Non-Small Cell Lung Cancer (NSCLC)
T Cell Lymphoma Forum (TCLF)
Jan 28-30, 2016
Induction of cell death by HBI-8000, an HDAC inhibitor, in adult T-cell leukemia/lymphoma (ATL) is associated with activation of Bim and NLRP
International Cancer Immunotherapy (ICI)
August 21–26, 2016
The HDAC inhibitor HBI-8000 enhances immunotherapy with either PD-1 or PD-L1 blockade in the MC38 and 4T1 models of colon cancer
American Society of Hematology (ASH)
December 3-6, 2016
Oral HDAC Inhibitor HBI-8000 in Japanese Patients with Non–Hodgkin Lymphoma (NHL): Phase I Safety and Efficacy Results
